Background and Importance The emergence of information and communication technologies has enabled the development of telepharmacy programmes (TPP) as a complementary tool to personal care, through which pharmaceutical care can be provided without the need to visit the hospital. TPP began in December 2019 with delivery of medication to primary healthcare centres previous pharmaceutical care by telephone from the hospital pharmacy.

Aim and Objectives Describing the pharmaceutical interventions (PI) of patients included in a TPP

Material and Methods Prospective, descriptive study, from december 2019-september 2022. Pharmacotherapy follow-up consisted of structured telephone interviews scheduled every 3 months. Inclusion criteria: duration of treatment greater than3 months, stable chronic disease, adherence greater than 90%, good tolerance to medication and/or mobility or dependency problems. Exclusion criteria: onco-haematological treatment, and patients with cognitive problems, or technological barriers to telephone pharmacotherapeutic follow up.

PI were classified as: drug-drug interactions (DDI), clinical monitoring (CM), adverse drug reactions (ADR) and/or lack of efficacy (LOF). In addition, the results of each PI were recorded as: temporary/permanent discontinuation (TPD), change of treatment (ChOT), change of dosing regimen (ChDR) or continuation of treatment (COT). The degree of acceptance of the Pi was calculated.

Results A total of 4.497 telephone interviews were conducted with 410 patients included in the TPP. Fifty-seven percent of treatments were biologics, 27% antiretrovirals, 6% multiple sclerosis/amyotrophic lateral sclerosis treatment, 3% lipid-lowering drugs, 3% somatropins, 2% pulmonary antihypertensives and 2% other drugs.

88 Pi were registered, 58% of which were accepted by the prescribing physician.

Conclusion and Relevance Pharmacotherapeutic monitoring of patients included in the TPP mainly allowed for the detection of ADRs and ensured adequate clinical supervision of in-patient medication.

The outcome of the interventions was mostly COT followed by modification of the prescribed regimen.

The pharmacist´s activity in a TPP can contribute to a better use of medicines, as well as prevent and solve medication-related problems.

Conflict of Interest No conflict of interest